Literature DB >> 8951769

Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.

A Georgii1, T Buhr, G Buesche, A Kreft, H Choritz.   

Abstract

The present study illustrates characteristic features of histopathology in the 3 non-leukemic, Ph-negative groups of chronic myeloproliferative diseases (CMPD). Attention is paid to the final outcome of CMPD, especially its transformation into acute leukemias and the occurrence of myelofibrosis from bone marrow biopsies (BMB) in a total of 1,716 CMPD patients. Essential thrombocythemia (ET), polycythemia vera (P. vera), and chronic megakaryocytic granulocytic myelosis (CMGM) can readily be distinguished by histopathology from BMB in the great majority of patients without regarding laboratory data, leaving a compartment of about 12% unclassifiable cases. Histologic patterns of staging are the increase in number and pleomorphism of megakaryocytes (MK), increase in number and density of reticulin fibers and collagen fibrosis, and excess of blasts. These 3 criteria are each graded from 0 to 3 in every biopsy. From these, a staging results by means of the histology of BMB in each of the Ph-negative CMPD. This staging provides a classification by defined criteria which permits comparative studies, the possibility of monitoring the individual patients by follow-up histology, and offers a baseline for reliable evaluation of results from therapy protocols.

Entities:  

Mesh:

Year:  1996        PMID: 8951769     DOI: 10.3109/10428199609074357

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool.

Authors:  Zbigniew Rudzki; Rafał Kawa; Krzysztof Okoñ; Ewa Szczygieł; Jerzy Stachura
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

2.  Frequency of pseudo-Gaucher cells in diagnostic bone marrow biopsies from patients with Ph-positive chronic myeloid leukaemia.

Authors:  G Büsche; H Majewski; J Schlué; S Delventhal; S Baer-Henney; K F Vykoupil; A Georgii
Journal:  Virchows Arch       Date:  1997-02       Impact factor: 4.064

Review 3.  [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].

Authors:  K Hussein; G Büsche; J Schlue; U Lehmann; H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

4.  Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders.

Authors:  S Duensing; A Duensing; J G Meran; A Kreft; G Büsche; A Ganser; A Georgii
Journal:  Mol Pathol       Date:  1999-06

Review 5.  Rethinking the diagnostic criteria of polycythemia vera.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2013-12-19       Impact factor: 11.528

6.  European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.

Authors:  Thomas Buhr; Konnie Hebeda; Vassiliki Kaloutsi; Anna Porwit; Jon Van der Walt; Hans Kreipe
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 7.  Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 8.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 9.  Essential thrombocythemia.

Authors:  Jean B Brière
Journal:  Orphanet J Rare Dis       Date:  2007-01-08       Impact factor: 4.123

Review 10.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.